At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -3.12: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.23BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9380xvs all stocks
52-Week Change
27.82%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
1.23BUSDvs all stocks (USD)
Enterprise Value
1.09BUSDvs all stocks (USD)
Forward P/E
-6.86xvs Biotechnology peers
Price to Book (MRQ)
9.91xvs Biotechnology peers
Enterprise to EBITDA
-3.76xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-51.30%vs Biotechnology peers
Return on Equity (TTM)
-134.29%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-290.44MUSDvs all stocks (USD)
Net Income (TTM)
-297.01MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-279.06MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-171.67MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2026 · Mar 31, 2026Operating Income
-318.31MUSDvs all stocks (USD)
Pre-tax Income
-314.49MUSDFY2026 · Mar 31, 2026Income Tax Expense
-551.00KUSDFY2026 · Mar 31, 2026Net Income
-313.94MUSDFY2026 · Mar 31, 2026EBIT
-305.63MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
-315.93MUSDFY2026 · Mar 31, 2026Research & Development
221.18MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
98.73MUSDFY2026 · Mar 31, 2026Other Operating Expenses
-1.60MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
8.86MUSDFY2026 · Mar 31, 2026EPS (Basic)
-3.38USDFY2026 · Mar 31, 2026EPS (Diluted)
-3.38USDFY2026 · Mar 31, 2026Basic Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
92.80MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-313.94MUSDFY2026 · Mar 31, 2026Operating Cash Flow
-279.00MUSDFY2026 · Mar 31, 2026Free Cash Flow
-283.22MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
210.73MUSDFY2026 · Mar 31, 2026Income Tax Paid
5.00KUSDFY2026 · Mar 31, 2026Interest Paid
4.69MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-313.94MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
3.33MUSDFY2026 · Mar 31, 2026Stock-based Compensation
32.27MUSDFY2026 · Mar 31, 2026Other Non-cash Items
5.13MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
451.00KUSDFY2026 · Mar 31, 2026Change in Accounts Payable (CF)
-4.94MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.30MUSDFY2026 · Mar 31, 2026Capital Expenditures
-4.22MUSDFY2026 · Mar 31, 2026Purchase of Investments
-77.89MUSDFY2026 · Mar 31, 2026Sale of Investments
392.96MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
310.84MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
35.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-736.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
65.41MUSDFY2026 · Mar 31, 2026Shares Outstanding
83.98MSharesUpdated Oct 28, 2026Float Shares
67.65MSharesUpdated Oct 28, 2026Shares Short
23.13MSharesUpdated Oct 28, 2026Short Ratio
10.98daysvs all stocks
Short % of Shares Outstanding
34.24%vs all stocks
% Held by Insiders
1.65%vs all stocks
% Held by Institutions
105.80%vs all stocks
Total Cash (MRQ)
195.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.07USDUpdated Oct 28, 2026Total Debt (MRQ)
111.97MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.06xvs Biotechnology peers
Current Ratio (MRQ)
5.23xvs Biotechnology peers
Book Value per Share (MRQ)
1.26USDUpdated Oct 28, 2026Total Assets
332.39MUSDvs all stocks (USD)
Total Current Assets
279.12MUSDFY2026 · Mar 31, 2026Total Liabilities
166.23MUSDFY2026 · Mar 31, 2026Total Non-current Assets
53.27MUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
108.00MUSDFY2026 · Mar 31, 2026Total Current Liabilities
58.23MUSDFY2026 · Mar 31, 2026Cash
88.72MUSDFY2026 · Mar 31, 2026Cash Equivalents
120.30MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
209.02MUSDFY2026 · Mar 31, 2026Other Short-term Investments
59.87MUSDFY2026 · Mar 31, 2026Accounts Payable
6.67MUSDFY2026 · Mar 31, 2026Short-term Debt
4.04MUSDFY2026 · Mar 31, 2026Other Current Liabilities
2.76MUSDFY2026 · Mar 31, 2026Long-term Debt
107.55MUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
455.00KUSDFY2026 · Mar 31, 2026Common Stock (Book)
82.00KUSDFY2026 · Mar 31, 2026Retained Earnings
-1.26BUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
166.16MUSDvs all stocks (USD)
52-Week Low
1.50USDUpdated Oct 28, 202652-Week High
16.33USDUpdated Oct 28, 202652-Week Change
27.82%vs all stocks
Beta
0.9380xvs all stocks
50-Day MA
13.48USDUpdated Oct 28, 2026200-Day MA
9.13USDUpdated Oct 28, 2026Avg 10-Day Volume
1.77MSharesUpdated Oct 28, 2026Avg 30-Day Volume
1.96MSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-3.15USDUpdated Oct 28, 2026Other Income / Expense
12.68MUSDFY2026 · Mar 31, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.23Altman Z-Score: -3.12
Financial Health
Altman Z-Score -3.12: distress zoneCritical
Altman Z-Score: -3.12
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Market cap is $1.23B, above the global median of $1.14BNotable
Market cap (USD): 1,229,566,223Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Carsgen Therapeutics Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vor Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking